A 2-year prospective evaluation of the Prostate Health Index in guiding biopsy decisions in a large cohort.
Peter Ka-Fung ChiuAlex Qinyang LiuSui-Yan LauJeremy Yuen Chun TeohChi-Chun HoChi-Hang YeeSee-Ming HouChi-Kwok ChanWai-Lun TangChris H BangmaPeggy Sau-Kwan ChuWing-Tat PoonChi-Fai NgMonique J RoobolPublished in: BJU international (2024)
In a real-life setting, with the PHI incorporated into the routine clinical pathway, 83% of the patients with elevated PSA level decided not to undergo prostate biopsy. The PHI pathway also improved the high-grade prostate cancer detection rate when compared to PSA-driven strategies. Higher baseline PHI predicted subsequent biopsy outcome at 2 years. The PHI can serve as a tool to individualise biopsy decisions and frequency of follow-up visits.